Edition:
United States

Tigenix NV (TIG.OQ)

TIG.OQ on NASDAQ Stock Exchange Global Select Market

40.77USD
23 Feb 2018
Change (% chg)

$-1.15 (-2.74%)
Prev Close
$41.92
Open
$42.33
Day's High
$42.33
Day's Low
$40.77
Volume
194
Avg. Vol
3,544
52-wk High
$43.94
52-wk Low
$14.34

Select another date:

Thu, Jan 18 2018

BRIEF-Tigenix Says Received Transparency Notification From Jpmorgan Chase & Co​ On Jan 16

* ‍TRANSPARENCY NOTIFICATION PURSUANT TO ARTICLE 14 OF LAW OF MAY 2, 2007​‍

Japan's Takeda to acquire TiGenix for $630 mln

TOKYO, Jan 5 Japan's Takeda Pharmaceutical Co said on Friday it has agreed to buy Belgian biotech group TiGenix NV for 520 million euros ($628 million).

BRIEF-Tigenix Confirms Strategic Focus On Cx601 And Its Adipose Derived Stem Cell Platform

* CONFIRMS STRATEGIC FOCUS ON CX601 AND ITS ADIPOSE DERIVED STEM CELL (EASC) PLATFORM Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Tigenix Plans To Focus On Its eASC Platform And Product Candidates Cx601 And Cx611

* TIGENIX NV SAYS PLANS TO FOCUS ITS RESOURCES AND CAPABILITIES ON ITS EASC PLATFORM TECHNOLOGY AND ITS PRODUCT CANDIDATES CX601 AND CX611 Source text for Eikon: Further company coverage:

BRIEF-Takeda And Tigenix Announces That CX601 Has Received a Positive CHMP Opinion

* REG-TAKEDA AND TIGENIX ANNOUNCE THAT CX601 (DARVADSTROCEL) HAS RECEIVED A POSITIVE CHMP OPINION TO TREAT COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE

BRIEF-Tigenix Nv - Mesoblast Grants Access To Patents To Support Commercialization Of Adipose-Derived Mesenchymal Stem Cell Product Cx601 For Treatment Of Fistulae​

* - MESOBLAST GRANTS ACCESS TO PATENTS TO SUPPORT COMMERCIALIZATION OF ADIPOSE-DERIVED MESENCHYMAL STEM CELL PRODUCT CX601 FOR TREATMENT OF FISTULAE​

BRIEF-JP Morgan Chase & Co notifies 3.12 pct shareholding in Tigenix​

* ‍JP Morgan Chase & Co notifies 3.12 pct shareholding in Tigenix​ Source text for Eikon: Further company coverage:

BRIEF-Tigenix announces approval of trade name for CX601 in Europe

* TIGENIX ANNOUNCES APPROVAL OF TRADE NAME FOR LEAD DEVELOPMENT CANDIDATE CX601 IN EUROPE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Tigenix announces partial conversion of bonds

* ‍ANNOUNCES CONVERSION OF EUR 7 MILLION OF COMPANY'S SENIOR UNSECURED CONVERTIBLE BONDS DUE 2018​

BRIEF-Tigenix obtains patent for Cx601 lead development program

* REG-TIGENIX STRENGTHENS EUROPEAN IP PROTECTION AROUND LEAD DEVELOPMENT PROGRAM CX601

Select another date: